

List of Contents

Part 1. Basic Principles: Pharmacologic Science

Biochemical and Physiological Processes in Brain Function and Drug Actions	3
<i>W.D. Horst</i>	
General Principles of Pharmacokinetics	35
<i>S.H. Preskorn, M.L. Catterson</i>	
Therapeutic Drug Monitoring of Antidepressants	87
<i>M.J. Burke, S.H. Preskorn</i>	

Part 2. Basic Principles: Clinical Science

Biological Markers of Depression	117
<i>T.J. Connor, B.E. Leonard</i>	
Quality of Life and Rating Scales of Depression	149
<i>P. Bech</i>	

Part 3. Current Pharmacotherapy of Major Depressive Disorder

Overview of Currently Available Antidepressants	171
<i>S.H. Preskorn, R. Ross</i>	
Tricyclic Antidepressants	185
<i>M. Lader</i>	
Monoamine Oxidase Inhibitors	209
<i>S.H. Kennedy, A. Holt, G.B. Baker</i>	
Selective Serotonin Reuptake Inhibitors	241
<i>S.H. Preskorn, R. Ross, C. Y. Stanga</i>	
Other Antidepressants	263
<i>S.H. Preskorn, R. Ross</i>	

Current Role of Herbal Preparations	325
<i>D. Wheatley</i>	

Part 4. Use of Antidepressants in Special Populations

Children and Adolescents	355
<i>J.F. Bober, S.H. Preskorn</i>	
Women	379
<i>K.A. Yonkers, O. Brawman-Mintzer</i>	
Older Adults	393
<i>S. Glover, W.F. Boyer</i>	
Bipolar Mood Disorders	421
<i>R.D. Alarcon</i>	
Treatment-Refractory Depression	447
<i>M. Trivedi, T. Bettinger, B. Kleiber</i>	
Personality Disorders	489
<i>M.L. Wainberg, A.J. Kolodny, L.J. Siever</i>	

Part 5. Future Directions in the Treatment of Major Depressive Disorder

New Hypotheses to Guide Future Antidepressant Drug Development	519
<i>I. Nalepa, F. Sulser</i>	
Promising New Directions in Antidepressant Development	565
<i>V. Garlapati, W.F. Boyer, J.P. Feighner</i>	
Role of Pharmacogenetics/Pharmacogenomics in the Development of New Antidepressants	583
<i>S.H. Preskorn</i>	
Appendix	597
Subject Index	609